Navigation Links
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Date:11/1/2009

SAN DIEGO and OSAKA, Japan, Nov. 1, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in phase 2 development for treatment of obesity. The agreement also includes additional compounds from both companies' obesity research programs. Amylin will receive a one-time up-front payment of $75 million from Takeda and, over the term of the agreement and in relation to the compounds under the agreement, is eligible to receive additional payments upon achieving certain development, commercialization and sales-based milestones that could exceed $1 billion. The agreement also provides for future tiered, double-digit royalty payments to Amylin based on global product sales.

Under the terms of the agreement, Amylin will be responsible for executing development activities for potential products through phase 2 with the aim of regulatory approval in the U.S. Takeda will lead development activities beyond phase 2 in the U.S., and all development activities outside the U.S. In most instances, Amylin will be responsible for 20% of development costs associated with obtaining approval for products in the U.S. and Takeda will be responsible for 80% of such U.S. development costs. Takeda will be responsible for 100% of development costs associated with obtaining approval for products outside the U.S.

Takeda will lead product commercialization, both in the U.S. and outside the U.S., and
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Lilly and Amylin Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
11. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... ... As part of the celebration of its 70th anniversary, the Thantakit International Dental ... around the world for their continuous patronage of the world-class services of their international ... Thantakit is one of the foremost places for dental tourism in Thailand) or locals ...
(Date:7/1/2015)... ... July 01, 2015 , ... A June 19th article by the Associated Press discussed ... down on the cost of medical care, specifically for seniors. Medicare recently completed the first ... already saved $25 million. Medicare’s chief medical officer, Dr. Patrick Conway said that “If we ...
(Date:7/1/2015)... ... July 01, 2015 , ... The federal court ... http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. According to an ... June 26th, the Court rejected the Plaintiff’s assertion that one manufacturer can ...
(Date:7/1/2015)... ... July 01, 2015 , ... Ormco Corporation, ... that its fifth annual Smile for a Lifetime Foundation (S4L) fundraising event held ... In addition to supporting S4L in its mission to provide free quality orthodontic ...
(Date:7/1/2015)... ... 01, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Rhinoplasty Symposium . Set for March 6th - 8th, the 2016 meeting will be ... basic training and fundamentals of nasal surgery through the most modern advancements and updates ...
Breaking Medicine News(10 mins):Health News:Thailand's Longest Established International Dental Center Celebrates Its 70th Anniversary with Promos Galore 2Health News:Article Announcing Medicare’s Cost Cutting Suggestions Shines Brightly on House Call Medicine, Comments Dr. Michael Farzam 2Health News:Article Announcing Medicare’s Cost Cutting Suggestions Shines Brightly on House Call Medicine, Comments Dr. Michael Farzam 3Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 3
... Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that ... (GBM) has a favorable safety profile and extends survival ... median survival rate. Patients in the study, conducted ... San Francisco and Columbia University, were found to have ...
... the most vulnerable group are the elderly. Writing in ... in New Zealand suggest that emergency response plans must ... regards to the personal and social resources they have ... University in Palmerston North, point out that elderly citizens ...
... is one of the leading causes of death. Chronic, localized ... fibrous plaques, which leads to narrowing or occlusion of the ... of the inflammatory reaction is due to a loss of ... cells are known to play a central role in the ...
... 2011Hospitals that provide quality care for young people do not ... new study has found. As our population ages and ... care they provide for the over 65s and implement programs ... Avery Nathens, trauma director at St. Michael,s Hospital. The ...
... HealthDay Reporter , THURSDAY, June 2 (HealthDay News) -- ... coli bacteria in Europe should serve as a red ... constantly mutating and changing. They,re not necessarily becoming more severe, ... an attending physician in infectious diseases at North Shore University ...
... (HealthDay News) -- They are meant to protect football players, ... faceshields are more likely to break on high-velocity impact. ... State University, also found that only about 50 percent of ... used or damaged shields. In the study, published in ...
Cached Medicine News:Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 4Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 5Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 6Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 7Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 8Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 9Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 10Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 11Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 12Health News:Helping the aged during natural disasters 2Health News:Fast track to vascular disease 2Health News:Fast track to vascular disease 3Health News:Not all hospitals treat elderly the same 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 3Health News:Used Football Faceshields May Break on Impact 2
(Date:7/1/2015)... YORK, Pa. , July 1, 2015  Unilife ... developer, manufacturer and supplier of injectable drug delivery systems, ... been amended as of June 30, 2015. This amendment ... least $20 million in cash receipts from customers during ... no other adjustments to any of the terms of ...
(Date:7/1/2015)... Qiming Venture Partners, today announces the promotion ... immediately. William has been with Qiming for ... many Qiming healthcare deals, and assisted many of these ... s success in healthcare is not a small part ... his outstanding advocacy and service mentality on behalf of ...
(Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
Breaking Medicine Technology:Unilife and OrbiMed Amend Debt Financing Agreement 2Unilife and OrbiMed Amend Debt Financing Agreement 3Qiming Announces the Promotion of William Hu to Managing Partner 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4
... Oct. 5 Alma Lasers, a global developer, ... ultrasound devices for aesthetic and medical applications announced ... supporters committed to fighting breast cancer through awareness, ... Awareness and the newly launched SopranoXLi Pain-Free Hair-Free ...
... Oct. 5 According to Millennium Research Group (MRG), ... Canadian interventional cardiology device market is a highly competitive ... competitors fighting for market share in this extremely profitable ... a $55 million market -- the most lucrative of ...
Cached Medicine Technology:Alma Lasers Joins the Fight Against Breast Cancer with the Launch of the NEW SopranoXLi 2Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market 2Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market 3
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Medicine Products: